Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth
Woman and Man Max 99 years
Pfizer (formerly Wyeth) (UK)
Update Il y a 4 ans
Low dose etanercept for the treatment of patients with ankylosing spondylitis
Background and study aims In people with ankylosing spondylitis (AS) a protein called tumour necrosis factor (TNF) is overproduced in the body, causing inflammation and damage to bones, cartilage and...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF 4 DOSE REGIMENS OF PLA-695, NAPROXEN, AND PLACEBO ADMINISTERED DAILY FOR 6 WEEKS IN SUBJECTS WITH ACTIVE OSTEOARTHRITIS OF THE KNEE
To establish efficacy and safety of PLA-695 in subjects with active OA of the knee.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous (IV) Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus
To test the following hypothesis: in patients who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter in the MOA-728 regimen than ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Demonstration of the safety and efficacy of ReFacto AF administered by bolus injection or continuous infusion during the perioperative management of patients with hemophilia A undergoing major surgery
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE WITH DONEPEZIL AS ACTIVE CONTROL
The primary objective is to determine the safety, tolerability, and efficacy of 3 doses of Lecozotan (SRA-333) SR (2 mg, 5 mg and 10 mg) in patients with mild to moderate AD over 12 weeks.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
B1931003 : Essai de phase 1 évaluant 2 types de chimiothérapie en combinaison avec l’inotuzumab ozogamicin, chez les patients avec un lymphome non-hodgkinien. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer une chimiothérapie en combinaison avec l’inotuzumab ozogamicin chez les patients avec un lymphome non-hodgkinien. Dans le premier groupe, les patients recevront ...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman
Between 18 years
and 99 years
Wyeth
Update Il y a 4 ans
WYETH 3160A6-2206 : Essai de phase 2 randomisé évaluant l'efficacité et la tolérance de l'exémestane associé ou non à du bosutinib, en traitement de 2ème ligne chez des patientes ménopausées ayant un cancer du sein localement avancé ou métatstatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase 2, randomized, open-label study of bosutinib administered in combination with exemestane versus exemestane alone as second line therapy in postmenopausal women with locally advanced or metasta...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals
Update Il y a 4 ans
A multicenter study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital hemophilia A who develop de novo factor VIII inhibitors while receiving factor VIII infusion therapy
The objective of this study is to describe the patterns of antibodies and associated epitopes in a subset of patients with hemophilia A, who meet the protocol entry criteria, using the methodology des...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo- And Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with Menopause
To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate
To assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active Rheumatoid Arthritis on a background of methotrexate.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next